Morphosys Ag

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Daiichi Sankyo Company, Limited

Ingrid Schuster

Stefanie Urlinger

Thomas Tiller

Yvonne Stark

Dirk H Busch

Angela Krackhardt

Tohru Takahashi

Eisuke Tsuda

Yoshiharu Hiruma

Toshinori Agatsuma

Toshiaki Ohtsuka

Tatsuji Matsuoka

Ichiro Watanabe

Sandra Miller

Ulrike Schubert

Dirk Ponsel

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Steffen Runz

The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.

Collection and methods for its use

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

The present invention is directed to a T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1/KW13 and being capable of inducing peptide specific killing of a target cell. The present invention is further directed to one antigenic peptides derived from tumor-associated antigen FMNL1/KW13, to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of FMNL1/KW13.

Allorestricted peptide-specific T cells

Growing community of inventors

Munich, Germany

Ingrid Schuster